Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the company's initiation of a rolling submission of a biologics license ap
Denali Therapeutics: Vast Pipeline, First Approval Up Ahead
02:16pm, Thursday, 20'th Mar 2025
Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 sh
Why You Shouldn't Bet Against Denali (DNLI) Stock
10:00am, Thursday, 20'th Mar 2025
Denali (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus
02:16pm, Friday, 28'th Feb 2025
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for tividenofusp alfa for the treatment of MPS II (Hunter syndrome).
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
04:01pm, Thursday, 27'th Feb 2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and pro
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
10:56am, Friday, 07'th Feb 2025
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndr
Denali Gains 26.6% in a Year: How Should You Play the Stock?
07:16am, Tuesday, 21'st Jan 2025
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost.
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
02:26pm, Wednesday, 15'th Jan 2025
Denali Therapeutics Inc DNLI CEO Ryan Watts presented at the J.P. Morgan Healthcare Conference.
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
03:56pm, Thursday, 09'th Jan 2025
Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
12:30pm, Thursday, 09'th Jan 2025
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
03:16pm, Tuesday, 07'th Jan 2025
DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.
Denali Therapeutics ALS drug fails in mid-stage trial
04:43pm, Monday, 06'th Jan 2025
Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disea
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platfor
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
01:08pm, Friday, 03'rd Jan 2025
William Blair has initiated coverage on Denali Therapeutics Inc DNLI, a company focused on developing drugs for neurodegenerative diseases.
